
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.
In today’s ACT Brief, we examine how trial matching built into standard care can replace reliance on physician memory, how federal funding cuts and FDA staff losses are pressuring biotech, and why FDA is without a commissioner nominee after the White House withdrew Heidi Overton.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.






